抗核小体抗体、抗C1q抗体和抗双链DNA抗体在狼疮肾炎诊断中的意义

吉林大学学报(医学版) ›› 2017, Vol. 43 ›› Issue (04): 757-761.doi: 10.13481/j.1671-587x.20170419

• 临床研究 • 上一篇下一篇

抗核小体抗体、抗C1q抗体和抗双链DNA抗体在狼疮肾炎诊断中的意义

尹芳蕊^1,2, 庞春艳^1,2, 吕凤凤^1,2, 张文兰¹, 赵剑波¹, 王永福^1,2

1. 包头医学院第一附属医院风湿免疫科包头医学院风湿免疫研究所, 内蒙古包头 014010;
2. 内蒙古自治区自体免疫学重点实验室, 内蒙古包头 014010

收稿日期:2016-12-04 出版日期:2017-07-28 发布日期:2017-08-01
通讯作者: 王永福,主任医师,硕士研究生导师(Tel:0472-2178469,E-mail:yfrjiayou@yeah.net) E-mail:yfrjiayou@yeah.net
作者简介:尹芳蕊(1981-),女,内蒙古自治区包头市人,主管检验师,医学硕士,主要从事风湿免疫疾病实验室检查方面的研究。
基金资助:
国家自然科学基金资助课题（30960354）

Significance of anti-nucleosome antibody,anti-C1q antibody and anti-double stranded DNA antibody in diagnosis of lupus nephritis

YIN Fangrui^1,2, PANG Chunyan^1,2, LYU Fengfeng^1,2, ZHANG Wenlan¹, ZHAO Jianbo¹, WANG Yongfu^1,2

1. Department of Rheumatology, First AffiliatedHospital, Baotou Medical College, Institute of Immunology and Rheumatology, Baotou Medical College, Baotou 014010, China;
2. Inner Mongolia Key Laboratory of Autoimmunity, Baotou 014010, China

Received:2016-12-04 Online:2017-07-28 Published:2017-08-01

摘要/Abstract

摘要： 目的：通过抗核小体抗体、抗C1q抗体和抗双链DNA（dsDNA）抗体检测，观察3种抗体阳性的狼疮肾炎（LN）患者实验室检查和临床特征，阐明系统性红斑狼疮（SLE）并发LN的危险因素及3种抗体在LN诊断中的意义。方法：选择SLE患者120例，其中LN组60例，非LN组60例，回顾性分析2组患者抗核抗体谱及抗C1q抗体的差异；比较LN组患者抗核小体抗体、抗C1q抗体和抗dsDNA抗体3种抗体阳性的LN患者（三阳性LN组）和非抗体阳性的LN患者（非三阳性LN组）的临床表现及实验室检查的差异。结果：LN组患者抗C1q抗体阳性率为40.00%，非LN组患者抗C1q抗体阳性率为21.67%，2组患者抗C1q抗体阳性率比较差异有统计学意义（χ²=4.728，P=0.03）；LN组患者抗dsDNA抗体阳性率为66.67%，非LN组患者抗dsDNA抗体阳性率为46.67%，2组患者抗dsDNA抗体阳性率比较差异有统计学意义（χ²=4.887，P=0.027）；LN组患者抗核小体抗体阳性率为58.33%，非LN组患者抗核小体抗体阳性率为40.00%，2组患者抗核小体抗体阳性率比较差异有统计学意义（χ²=4.034，P=0.045）；其余抗体U1-snRNP、SmD1、Jo-1、SSA/Ro60kD、SSA/Ro52kD、SSB、scl-70、CENP-B和P0抗体阳性率组间比较差异均无统计学意义（P>0.05）。三阳性LN组与非三阳性LN组患者年龄及免疫球蛋白、C反应蛋白（CRP）、血沉、白细胞和血小板检测结果比较差异均无统计学意义（P>0.05），三阳性LN组患者补体C3、补体C4和血红蛋白水平较非三阳性LN组降低（P<0.05）。三阳性LN组和非三阳性LN组患者不同临床症状发生率比较差异无统计学意义（P>0.05）。结论：抗核小体抗体、抗C1q抗体和抗dsDNA抗体是SLE并发LN的危险因素，三抗体阳性可提高LN的诊断率，三阳性LN组患者补体和血液系统方面损害更严重，肾疾病活动度更高。

关键词: 抗C1q抗体, 抗核小体抗体, 抗双链DNA抗体, 狼疮肾炎

Abstract: Objective: To investigate the clinical and laboratory characteristics of lupus nephritis(LN) patients by detecting the anti-nucleosome antibodies, anti-C1q antibodies and anti-double stranded antibodies(anti-ds DNA), and to clarify the risk factors of LN in the patients with systemic lupus erythematosus(SLE),and the significance of three kinds of antibodies in diagnosis of LN.Methods: A total of 120 SLE patients were selected and divided into LN group(n=60) and non-LN group(n=60).The ANAS data of 120 patients were retrospectively analyzed,the levels of anti-C1q antibodies were measured.The clinical symptoms and laboratory data of the patients with positive anti-dsDNA, -nucleosome and -C1q antibodies (3-pos group)and negative three kinds of antibodies(non 3-pos group) were analyzed in LN group.Results: The positive rate of anti-C1q antibody of the patients in LN group (40.00%) was higher than that in non-LN group (21.67%) (χ²=4.728, P=0.03).The positive rate of anti-dsDNA antibody in LN group was 66.67%, and it was 46.67% in non-LN group; the positive rates of the patients had significant difference between two groups (χ²=4.887, P=0.027). The positive rate of anti-nucleosome antibody in LN group was 58.33%, and it was 40.00% in non-LN group; the positive rates of the patients had significant difference between two groups (χ²=4.034, P=0.045).The positive rates of U1-snRNP, SmD1 and other antibodies Jo-1, SSA/Ro60kD, SSA/Ro52kD, SSB, ScL-70, CENP-B,and P0 had no significant differences between two groups(P>0.05). The levels of C3 and C4 and hemoglobinin of the patients in 3-pos group were higher than those innon 3-pos group (P<0.05);the age,the levels of immunoglobulin protein and C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), white blood cell (WBC) and platelet had no statistically significant differences between 3-pos and non 3-pos groups(P>0.05).The clinical symptoms were not statistically significant in 3-pos and non 3-pos groups (P>0.05).Conclusion: The anti-nucleosome, anti-C1q and anti-dsDNA antibodies are the risk factors of SLE complicated with LN;the positive antibodies can improve the diagnostic rate of LN.The 3-pos patients have more severe damage in complements and blood system with higher renal disease activities.

Key words: anti-nucleosome antibody, lupus nephritis, anti-C1q antibody, anti-double stranded DNA antibody

中图分类号:

R593.24

尹芳蕊, 庞春艳, 吕凤凤, 张文兰, 赵剑波, 王永福. 抗核小体抗体、抗C1q抗体和抗双链DNA抗体在狼疮肾炎诊断中的意义[J]. 吉林大学学报(医学版), 2017, 43(04): 757-761.

YIN Fangrui, PANG Chunyan, LYU Fengfeng, ZHANG Wenlan, ZHAO Jianbo, WANG Yongfu. Significance of anti-nucleosome antibody,anti-C1q antibody and anti-double stranded DNA antibody in diagnosis of lupus nephritis[J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 757-761.

参考文献

[1] Karras A. Lupus nephritis:up-to-date[J]. Rev MedInterne, 2015, 36(2):98-106.
[2] Parikh SV, Alvarado A, Malvar A, et al. The kidney biopsy in lupus nephritis:past, present, and future[J].Semin Nephrol,2015, 35(5):465-477.
[3] Tang X, Huang Y, Deng W, et al. Clinical and serologic correlations and autoantibody clusters in systemic lupus erythematosus:a retrospective review of 917 patients in South China[J]. Medicine(Baltimore), 2010, 89(1):62-67.
[4] Jain D,Aggarwal HK,Kaverappa V,et al.Anti-dsDNA negativeand anti-Ro positive lupus nephritis:a report of a rare case[J].Reumatismo,2014,65(6):302-306.
[5] Tan Y, Song D, Wu LH, et al. Serum levels and renal depositionof C1q complement component and its antibodies reflectdisease activity of lupus nephritis[J]. BMC Nephrol, 2013, 14(1):63.
[6] Franchin G, Son M, Kim SJ, et al. Anti-DNA antibodies cross-react with C1q[J]. J Autoimmun, 2013, 44:34-39.
[7] Tunnicliffe DJ, Singh-Grewal D, Kim S, et al. Diagnosis, monitoring, and treatment of systemic lupus erythematosus:a systematic review of clinical practice guidelines[J]. Arthritis Care Res(Hoboken), 2015, 67(10):1440-1452.
[8] Ntatsaki E, Isenberg D. Risk factors for renal disease in systemic lupus erythematosus and their clinical implications[J]. Expert Rev Clin Immunol, 2015, 11(7):837-848.
[9] Davidson A. What is damaging the kidney in lupus nephritis?[J]. Nat Rev Rheumatol, 2016, 12(3):143-153.
[10] Crispin JC,Liossis SN,Kis-Toth K,et al.Pathogenesis of human systemic lupus erythematosus:recent advances[J].Trends Mol Med,2010,16(2):47-57.
[11] Katsumata Y, Miyake K, Kawaguchi Y, et al. Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis:a controlled study of 126 consecutive patients.[J].Arthritis Rheum,2011,63(8):2436-2444.
[12] Sui M,Lin Q,Xu Z,et al.Simultaneous positivity for anti-DNA,anti-nucleosome and anti-histone antibodies is a marker for more severe lupus nephritis[J].J Clin Immunol,2013,33(2):378-387.
[13] ZivkovicV, Stankovic A, Cvetkovic T, et al. Anti-dsDNA, Anti-nucleosome and anti-C1q antibodies as disease activity markers in patients with systemic lupus erythematosus[J]. Srp Arh Celok Lek, 2014, 142(7/8):431-436.
[14] Trad B,Ben Hassine H,Khalifa M,et al.Anti-Clq antibodies and systemic lupus erythematosus in the Tunisian population[J].Pathol Biol,2013,61(3):113-116.
[15] Ballanti E,Perricone C,Greco E,et al.Complement and autoimmunity[J]. Immunol Res,2013,56(2/3):477-491.
[16] Li Y,Fang X,Li QZ.Biomarker profiling for lupus nephritis[J].Genomics Proteomics Bioinformatics,2013,11(3):158-165.
[17] Yang XW, Tan Y, Yu F, et al. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis[J]. Nephrol Dial Transplant, 2012, 27(9):3552-3559.
[18] 张晓慧,张卓莉.C反应蛋白与系统性红斑狼疮的相关性[J].中华临床免疫和变态反应杂志,2014,8(1):45-51.
[19] 刘东伟,刘章锁.狼疮性肾炎诱导治疗的变迁[J].中国实用内科杂志,2015,35(6):471-474.

相关文章 1

Metrics

本文评价

推荐阅读 0